Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 327 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR... November 3, 2023 Working to Address Inequities in Cancer Care: 2021 ASCO Annual Meeting... July 8, 2021 FDA Says Breast Implant Cancer Risk Is Not Enough to Warrant... May 3, 2019 How to Cope With Taking Long-Term Medication June 27, 2023 Load more HOT NEWS Boy Born With Heart Defect Gets Surgery To Help It Triple... Navigating Your Care During Long-Term Cancer Survivorship COVID-19 Vaccines: Considerations for Special Populations Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive...
